The role of glucagon-like peptide 1 in glucose homeostasis and in other aspects of human physiology

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 11, 2009, Pages 743-751

  Franek, Edward ^a,b   Gajos, Grzegorz ^c,d   Gumprecht, Janusz ^e   Krȩtowski, Adam ^f   Zahorska Markiewicz, Barbara ^g   Małecki, Maciej T ^c  

^a Leczenia Nieswoistych Chorob Zapalnych Jelit   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g NZOZ Poradnia Leczenia Chorób Metabolicznych WAGA   (Poland)

Author keywords

GLP 1; Incretin axis; Insulin secretion; Intestinal hormones

Indexed keywords

ETANERCEPT; EXENDIN 4; GASTRIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; LIRAGLUTIDE; SOMATOSTATIN;

APOPTOSIS; BARIATRIC SURGERY; CELL PROLIFERATION; CELL PROTECTION; CONTINUOUS INFUSION; DIABETES MELLITUS; ELECTROLYTE BALANCE; FLUID INTAKE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GRAFT FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE ACTION; HUMAN; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REPERFUSION INJURY; REVIEW; SATIETY; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH SECRETION; TRANSCRIPTION REGULATION; VASODILATATION; WEIGHT REDUCTION;

EID: 72149128439     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.829     Document Type: Review

References (101)

1. Elrick H, Stimmler L, Hlad CJ Jr, Aray Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24: 1076-1082.
2. Dupré J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973; 37: 826-828.
3. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001; 142: 521-527.
4. MacDonald PE, El-Kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002, 51 Suppl 3: S434-S442.
5. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983; 302: 716-718.
6. Suda K, Takahashi H, Fukase N, et al. Distribution and molecular forms of glucagon-like peptide in the dog. Life Sci. 1989; 45: 1793-1798. (Pubitemid 19278822)
7. Rouillé Y, Martin S, Steiner DF. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem. 1995; 270: 26 488-26 496.
8. Damholt AB, Buchan AM, Holst JJ, et al. Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Endocrinology. 1999; 140: 4800-4808.
9. Wettergren A, Pridal L, Wøjdemann M, et al. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept. 1998; 77: 83-87. (Pubitemid 28467092)
10. Persson K, Gingerich RL, Nayak S, et al. Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J Physiol Endocrinol Metab. 2000; 279: E956-E962.
11. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995; 16: 390-410.
12. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004; 53: 654-662. (Pubitemid 38270634)
13. Ørskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and grucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993; 42: 658-661. (Pubitemid 23127154)
14. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes. 1995; 44: 1126-1131.
15. Duke-Cohan JS, Morimoto C, Rocker JA, et al. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol. 1996; 156: 1714-1721. (Pubitemid 26069303)
16. Ajami K, Abbott CA, Obradovic M, et al. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry. 2003; 42: 694-701. (Pubitemid 36133293)
17. De Meester I, Durinx C, Bal G, et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol. 2000; 477: 67-87.
18. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 1996; 318: 429-435.
19. Hansen L, Deacon CF, Ørskov C, et al. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999; 140: 5356-5363.
20. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24.
21. Wilmen A, Walkenbach A, Füller P, et al. The genomic organization of the human GLP-1 receptor gene. Exp Clin Endocrinol Diabetes. 1998; 106: 299-302. (Pubitemid 28457010)
22. Drucker DJ, Philippe J, Mojsov S, et al. Grucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987; 84: 3434-3438. (Pubitemid 17085418)
23. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-165.
24. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology. 1994; 134: 2156-2164.
25. Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. 2002; 143: 3152-3161.
26. Tourrel C, Bailbé D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001; 50: 1562-1570. (Pubitemid 33639596)
27. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003 Jan 3; 278: 471-478. (Pubitemid 36043598)
28. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999; 48: 2270-2276. (Pubitemid 30395416)
29. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002; 283: E745-E752.
30. Bregenhort S, Møldnip A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005; 330: 577-584. (Pubitemid 40417684)
31. Hui H, Nourparvar A, Zhao X, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology. 2003; 144: 1444-1455. (Pubitemid 36432086)
32. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004; 47: 806-815. (Pubitemid 38756992)
33. Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008; 57: 3281-3288.
34. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab. 2008; 34 Suppl 2: S73-S77.
35. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008; 86: 36-45.
36. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007; 83: 24-28. (Pubitemid 46104966)
37. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005; 353: 249-254. (Pubitemid 41058324)
38. Clancy TE, Moore FD Jr, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg. 2006; 10: 1116-1119.
39. Vidal J, Nicolau J, Romero F, et al. Long-term effects of Roux-en-Y gastric bypass surgery on plasma GLP-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab. 2009; 94: 884-891.
40. Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008; 86: 1658-1665.
41. Rickels MR, Mueller R, Markmann JF, Naji A. Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009; 94: 181-189.
42. Rickels MR, Naji A. Exenatide use in islet transplantation: words of caution. Transplantation. 2009; 87: 153.
43. Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit. 2005; 11: RA271-RA278.
44. Greig NH, Mattson MP, Perry T, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci. 2004; 1035: 290-315. (Pubitemid 40362340)
45. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003; 72: 603-612. (Pubitemid 36578646)
46. Perry T, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets. 2004; 5: 565-571. (Pubitemid 39004431)
47. Gilman CP, Perry T, Furukawa K, et al. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem. 2003; 87: 1137-1144. (Pubitemid 37485070)
48. Perry T, Holoway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory. Exp Neurol. 2007; 203: 293-301. (Pubitemid 46157226)
49. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroproection. Nat Med. 2003; 9: 1173-1179. (Pubitemid 37173702)
50. Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 diabetes? J Med. 2007; 65: 60-64.
51. MacLusky NJ, Cook S, Scrocchi, et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology. 2000; 141: 752-762.
52. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379: 69-72. (Pubitemid 26008136)
53. Gonzalez C, Benito V, Keller G, et al. Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Investig Drugs. 2006; 15: 887-895. (Pubitemid 44177842)
54. Abbott CR, Monteiro M, Small CJ et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005; 1044: 127-131. (Pubitemid 40616060)
55. Abbott CR, Small CJ, Sajedi A, et al. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat. Int J Obes. 2006; 30: 288-292. (Pubitemid 43237684)
56. Tachibana T, Oikawa D, Adachi N, et al. Intracerebroventricular injection of glucagon-like peptide-1 changes lipid metabolism in chicks. Comp Biochem Physiol A Mol Integr Physiol. 2007; 147: 1104-1108. (Pubitemid 46843634)
57. Osaka T, Endo M, Yamakawa M, et al. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by lower brainstem and sympathoadrenal system. Peptides. 2005; 26: 1623-1631. (Pubitemid 41169757)
58. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005; 115: 3554-3563. (Pubitemid 43121843)
59. Ayala JE, Bracy DP, James FD, et al. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its increatin action. Endocrinology. 2009; 150: 1155-1164.
60. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 2009; 29: 5916-5925.
61. Fujita Y, Wideman RD, Speck M, et al. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab. 2009; 296: E473-E479.
62. Kokrashvili Z, Mosinger B, Margolskee RF. Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones. Am J Clin Nutr. 2009; 90: 822S-825S.
63. Neary NM, Small CJ Druce MR. Peptide YY 3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005; 146: 5120-5127.
64. Greenfield JR, Farooqi IS, Keogh JM, et al. Oral glutamine increases circulating glucagon-like peptide-1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetes subjects. Am J Clin Nutr. 2009; 89: 106-113.
65. Tessari P, Kiwanuka E, Cristini M. Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes. Diabetes Metab Res Rev. 2007; 23: 378-385. (Pubitemid 47091241)
66. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101: 515-520. (Pubitemid 28084232)
67. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001; 86: 4382-4389.
68. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon like peptide-1 on glycaemic control, insulin sensitivity and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830. (Pubitemid 34233752)
69. Naslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004; 91: 439-446. (Pubitemid 38386908)
70. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009; 124: 44-56.
71. Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996; 38: 916-919.
72. Lugari L, Dei Cas A, Ugolotti D, et al. Glucagon-like peptide-1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res. 2004; 36: 111-115. (Pubitemid 38392252)
73. Camilleri M. Peripheral mechanisms in the control of appetite and related experimental therapies in obesity. Regul Pept. 2009; 156: 24-27.
74. Moran TH, Dailey MJ. Minireview: gut peptides: targets for antiobesity drug development? Endocrinology. 2009; 150: 2526-2530.
75. Wideman RD, Kieffer TJ. Mining incretin hormone pathways for novel therapies. Trends Endocrinol Metab. 2009; 20: 280-286.
76. Le Roux CW, Welboum R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007; 246: 780-785. (Pubitemid 350035654)
77. De Luis DA, Gonzalez Sagrado M, Conde R, et al. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab. 2007; 51: 134-138. (Pubitemid 46975991)
78. Burcelin R. The incretins: a link between nutrients and well-being. Br J Nutr. 2005; 93 Suppl 1: S147-S156.
79. Chaudhri OB, Wynne K, Bloom SR. Can Gut hormones control appetite and prezent obesity? Diabetes Care. 2008; 31 Suppl 2: S284-S289.
80. Ahloulay M, Dechaux M, Laborde K, et al. Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effect. Am J Physiol. 1995; 269: F225-F235.
81. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metabol. 2004; 89: 3055-3061. (Pubitemid 38766408)
82. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide 1 is involved in sodium and water homeostasis in humans. Digestion. 2006; 73: 142-150. (Pubitemid 44155916)
83. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol. 2002; 434: 163-167. (Pubitemid 34056575)
84. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003; 21: 1125-1135. (Pubitemid 36667866)
85. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-481.
86. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol. 1993; 265: L374-L381. (Pubitemid 2006731)
87. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287: E1209-E1215. (Pubitemid 39491964)
88. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-2350. (Pubitemid 351653542)
89. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005; 54: 146-151.
90. Nikolaidis LA, Mankad S, Sokes GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109: 962-965. (Pubitemid 38282847)
91. Bose AK, Mocanu MM, Carr RD, et al. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007; 21: 253-256.
92. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008; 118: 1250-1258.
93. Taegtmeyer H, Golfman L, Sharma S, et al. Unking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004; 1015: 202-213. (Pubitemid 38879491)
94. Kavianipour M, Ehlers MR, Malmberg K, et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003; 24: 569-578.
95. Luque MA, González N, Márquez L, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002; 173: 465-473. (Pubitemid 34704718)
96. Zhao T, Parikh P, Bhashyam S, e al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006; 317: 1106-1113. (Pubitemid 43764114)
97. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004; 110: 955-961. (Pubitemid 39128621)
98. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289: H2401-H2408. (Pubitemid 41698549)
99. Poornima I, Brown SB, Bhashyam S, et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008; 1: 153-160.
100. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12: 694-699. (Pubitemid 44881367)
101. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007; 100: 824-829. (Pubitemid 47268274)